Allergan + Galderma command 76% of #1-supplier slots among $100k+/mo practices
(vs. 57% survey-wide). Big practices consolidate around the two majors — challenger
brands like Evolus fall to 0% primary share at the top.
Supplier Footprint — All Respondents (n=152)
Supplier
% Order At All
% As #1 Supplier
Avg Discount
Allergan (Botox, Juvéderm)
77%
33%
11.9%
Galderma (Dysport, Restylane)
74%
24%
12.4%
Merz (Xeomin, Radiesse)
63%
9%
17.0%
Revance (Daxxify, RHA)
53%
14%
13.4%
Evolus (Jeuveau)
38%
9%
9.7%
Prollenium (Revanesse)
30%
3%
n<8
Hugel (Letybo)
16%
1%
n<8
Supplier Footprint — $100k+/mo Practices (n=49)
Supplier
% Order At All
% As #1 Supplier
Avg Discount
Allergan (Botox, Juvéderm)
94% +17
41% +8
14.8% +2.9
Galderma (Dysport, Restylane)
96% +22
35% +11
15.0% +2.6
Merz (Xeomin, Radiesse)
65%
12%
n<8
Revance (Daxxify, RHA)
59%
10%
n<8
Evolus (Jeuveau)
31% −7
0% −9
n<8
Prollenium (Revanesse)
22% −8
2%
n<8
Hugel (Letybo)
10%
0%
n<8
Notably higher than survey-wideNotably lower than survey-wide(deltas ≥±7pp for order/#1 share; ≥±2pp for discount)
+22 pp
Galderma ordering surges at the top — 74% → 96% among $100k+/mo practices. Allergan follows at 77% → 94%. Near-universal penetration.
0%
Evolus has zero primary share in the $100k+ tier (vs. 9% survey-wide). Prollenium and Hugel similarly shrink. Challenger brands are small-practice brands.
15.2%
$100k+ practices get higher discounts (vs. 12.9% overall) and only 8% don't know their discount (vs. 14%). They know what they're paying and order more often.
Why Primary Users Chose Them — % Ranking Factor as #1 (survey-wide)
Quality is #1 for every supplier — purple cells mark each supplier's differentiating #2 factor
Primary Supplier
n
Quality
Price
Patient Demand
Brand Trust
Pharma Rep
Allergan
50
52%
12%
26%
6%
4%
Galderma
37
49%
22%
11%
11%
8%
Merz
14
64%
7%
7%
21%
0%
Revance
21
52%
19%
5%
19%
0%
Evolus
14
64%
7%
21%
0%
7%
Read it as: Quality is the price-of-entry — every supplier's #1 driver. The real temperament split is the differentiator: Allergan users lean Patient Demand (26% — "my patients ask for Botox by name"). Galderma and Revance users lean Price (22% and 19%). Merz users lean Brand Trust (21%). Evolus users lean Patient Demand (21%) — fighting for the Allergan-style "asked for by name" position. Revance is a tie (Price and Brand Trust both 19%). Suppliers with fewer than 8 primary users (Prollenium n=4, Hugel n=1) omitted.